The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
17:00-21:00 : WELCOME EVENING (BIO INNOVATION)
Poster session, visit Bio Innovation, discover the regional biocluster & foodtruck
8:30 : REGISTRATION AND WELCOME COFFEE (KURSAAL BALLROOM)
9:00 : WELCOME ADRESS AND INTRODUCTION (KURSAAL)
Dr. Sylvain Perruche, RIGHT Institute, Besançon, FR
Laurent Deschamps, PMT President, Besançon, FR
Representative of the President of Grand Besançon Métropole
Representative of the President of the Bourgogne Franche Comté Region
09:20-12:30 : SESSION #1 « UPCOMING INNOVATIVE THERAPIES »
Chairpersons : upcoming
09:20 : Translational potential of human platelet secretome and EVs
Pr Thierry Burnouf, Taipei Medical University’s College, Taiwan
09:50 : : upcoming title
Dr Jeanne Volatron, Everzom, Paris, FR
(10:20 : GOLD SPONSOR SMALL TALK)
10:25 : BREAK – EXHIBITION HALL
11:15 : upcoming
xx, xx, xx, xx
11:45 : upcoming
xx, xx, xx, xx
(12:15 : GOLD SPONSOR SMALL TALK)
12:20-14:00 : LUNCH
13:00-14:30 : Exhibition Hall – B2B MEETINGS
14:00-14:30 : SYMPOSIUM #1
Innovations for CAR-T production – Cytiva
14:30-18:00 : SESSION #2 “ CAR-T CELLS AND BEYOND ”
Chairpersons : upcoming
14:30 : Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR-T Cell Cancer Immunotherapy
Dr Michael Mitchell, University of Pennsylvania, Philadelphia, USA
15:00 : From bench to bedside: Successfully translating science to therapy
MD Jens Hasskarl, Advesya, Paris, FR
15:30 : Upcoming title
Dr Sebastian Amigorena, Institut Curie ou Mnemo Tx ?, Paris, FR
(16:00 : GOLD SPONSOR SMALL TALK)
16:05 : BREAK – EXHIBITION HALL
16:45 : Upcoming title
Dr Carole Guillonneau, ,Nantes, FR
17:15 : CAR-T: pricing, efficiency and sustainability in France
Pr Gérard de Pouvourville, ESSEC Business School, Cergy-Pontoise, FR
18:00-19:30 : B2B MEETINGS OR VISIT OF BESANÇON
19:30 : COCKTAIL (KURSAAL)
(on registration only)
20:00 : EVENING RECEPTION (KURSAAL)
(on registration only)
8:30 : WELCOME COFFEE (KURSAAL)
9:00-12:00 : SESSION #3 “PATHWAYS FOR INNOVATIVE THERAPIES”
Chairpersons : upcoming
09:00 : How can you register your academic CART-cell product in the EU?
Dr Julio Delgado, Clinic Barcelona, Barcelona, SP
09:30 : Upcoming title
Dr Anaick Moisan, Etablissement Français du Sang, Saint Ismier, FR
10:00 : BREAK- EXHIBITION HALL
10:45 : Upcoming title
Dr Jo Montford , Scottish National Blood transfusion service , Edinburgh, Scotland
11:15 : Upcoming
11:45-12:15 : SYMPOSIUM #2
Platinum sponsor
12:00-14:00 : LUNCH
12:40-14:00 : Exhibition Hall – B2B MEETINGS
14:00-16:30 : SESSION #4 “CELL AND GENE THERAPIES”
Chairpersons : upcoming
14:00 : Upcoming title
Dr Stephane Maddens, Vetbiobank, Marcy-L’Etoile, FR
14:30 : Upcoming title
Dr Nathalie Labarriere, INCIT, UMR1302, Nantes, FR
15:00 : BREAK- EXHIBITION HALL
15:30 : Upcoming title
xx, xx, xx, xx
16:00 : Upcoming title
xx, xx, xx, xx
16:30-16 :45 : CONCLUSION & END OF CONGRESS
Dr Christophe Ferrand, RIGHT Institute, Besançon, FR
Renaud Gaudillière, PMT director
16:45-17:45 : B2B MEETINGS
16:45 – 18:00 BEER PARTY
Dr Marina DESCHAMPS – Right Institute (Besançon, FR), Dr Christophe FERRAND – Right Institute (Besançon, FR), Sylvain PERRUCHE – MedInn Pharma (Besançon, FR),
President-Elect and Board of Directors member of the International Society of Cell and Gene Therapy (ISCT) from May 2022. Previously Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020) leading the expansion of the industrial community, strengthening the...
En savoir +Dr Olivier Humbey (PhD) is a Business Developer at IQVIA offering international Real World Data solutions to Biotechs at each stage of their product life cycle development (from early clinical to post-marketing). He works strategically with cross department services to...
En savoir +Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...
En savoir +Jens Hasskarl is the chief medical officer of advesya, a French startup focused on developing lifesaving therapies. Prior to joining advesya, he was the chief medical officer of Tigen Pharma SA, a Swiss startup developing cellular therapies to fight solid...
En savoir +Julien Branchu focused his scientific career on the discovery of innovative therapeutic targets that could improve the daily lives of patients. After several internships in neuroscience field, he joined Pr. F. Charbonnier's group for his PhD. Using in vitro and...
En savoir +Thierry Burnouf, PhD, is a Distinguished Professor and Vice-Dean at the College of Biomedical Engineering, Taipei Medical University, Taiwan. He established and leads a research lab focusing on platelets and extracellular vesicles for regenerative medicine, cell therapy, and drug delivery....
En savoir +European Regulation (EC) No 1394/2007 created a new class of drugs in 2007 called : “Advanced Therapy Medicinal Products”, resulting from cellular and tissue engineering, genetic manipulation, and possibly combined with medical devices. More than fifteen years after the implementation...
En savoir +Prof de Pouvourville has graduated from Ecole Polytechnique in 1973 Formerly, he has led a career as a researcher in the field of health care economics and management, at Ecole polytechnique, at the French National School of Public Health and...
En savoir +Dr GUILLONNEAU is Director of Research CNRS, head of team 2 at the Center of Research in Transplantation and Translational Immunology (CR2TI) in Nantes, France and director of the FOCIS Center of Excellence Nantes University. After a Postdoc in the...
En savoir +Nathalie Labarriere is Inserm Research Director, in charge of the team 3 « Anti-tumor immunosurveillance and immunotherapy» and deputy director of the INCIT Unit (Immunology and new concepts in Immunotherapy). She started working in 1990 on tumor immunology in Nantes...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +After studying biology at the University of Sciences in Besançon, Sylvie defended her thesis based on cytogenetic and molecular prenatal diagnostic tools in Pr. Bresson's cytogenetics laboratories in Besançon. Then she went to Montreal, Quebec, as a laboratory coordinator at...
En savoir +Gavin joined MabDesign in 2019 and currently holds the position of Head of Scientific Affairs & Business Intelligence. In this role, Gavin oversees the strategic development and implementation of scientific initiatives including MabDesign’s Watchs editions, our multiple types of scientific...
En savoir +John De Vos is Professor of Embryology, Histology and Regenerative Medicine at the Faculty of Medicine of Montpellier, and head of the Cellular and Tissue Engineering Department of the University Hospital Center (CHU) of Montpellier. His research, at the Research...
En savoir +After a master's degree in genetics and a Ph.D. on the role of Gas6 protein and precursor cells in steatohepatitis and hepatic fibrosis, Agnès advised companies in many sectors, particularly in industry, as a consultant in innovation financing. She was...
En savoir +Dr. Julio Delgado is the Head of the Oncoimmunotherapy Unit and consultant haematologist at Hospital Clínic, Barcelona (HCB), researcher at IDIBAPS Biomedical Research Institute, and associate professor at the University of Barcelona. He has been involved in the clinical development...
En savoir +Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...
En savoir +